Objective. To elucidate the diversity of systemic lupus erythematosus (SLE) based on immunophenotyping.
Methods. Peripheral blood mononuclear cells were obtained from 143 SLE patients and 49 healthy individuals. Circulating B, T, and dendritic cells were defined using flow cytometric analysis as recommended by the Human Immunology Project Consortium. Based on these results, immunophenotypes were distinguished by principal components analysis (PCA), and cluster analysis was used to classify SLE patients into subgroups.
Results. The proportions of Treg and follicular helper T (Tfh) cells were higher in SLE patients than in healthy controls, whereas Th1 and Th17 cell proportions did not differ. Proportions of class-switched memory B cells and IgD-CD27-B cells were increased in SLE patients as well. The largest difference compared to the control group was observed in the proportion of plasmablasts, which was higher in SLE patients and correlated with disease activity as assessed with the British Isles Lupus Assessment Group index. PCA indicated that the immunophenotype of SLE patients consisted of abnormalities of the T and B cell axes. Cluster analysis showed that the SLE patients could be stratified into 3 subgroups (with high proportions of plasmablasts in all groups): patients who did not show the characteristic features (T cell-independent group), patients with a high percentage of Tfh cells (Tfh-dominant group), and patients with a high percentage of memory Treg cells (Treg-dominant group). The percentage of patients whose SLE was resistant to treatment was highest among the Tfh-dominant group.
Conclusion. Our study indicates that patients with active SLE can be divided into 3 subgroups based on T cell heterogeneity. Further immunophenotyping studies should help elucidate the pathogenesis of SLE and provide important information for the development of new therapies.
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by overproduction of autoantibodies by B cells and breaking self tolerance of T cells and dendritic cells (DCs).
Various immunologic abnormalities are involved in the development of SLE (1) . For instance, we (2, 3) and others (4-7) have described characteristic abnormalities of B cells in this disease. In particular, plasmablasts play a central role in the pathogenesis of SLE, through the production of anti-double-stranded DNA (anti-dsDNA) antibody (8) . CD41 T helper cells have an important role in disease progression and pathology (9) . There is evidence of a predominance of the Th1 cell subset in patients with lupus nephritis (10) and of defects in the homeostatic control of Th17 and natural Treg cell subpopulations contributing to SLE pathology (11) . Moreover, follicular helper T cells (Tfh cells), which are an essential helper subset for B cell maturation (12) , are increased in the peripheral blood (PB) of lupus patients (13) . Furthermore, plasmacytoid DCs (14) and macrophages (15) , which are involved in innate immunity, contribute to the initiation and perpetuation of autoimmunity in SLE.
Taken together, the above findings suggest that SLE is molecularly heterogeneous (16) . Therefore, it would be difficult to manage every case based on one kinetic molecular theory. This is evidenced by the fact that targeted therapy has not yet been established in the treatment of SLE, although it has been used in the treatment of rheumatoid arthritis for as long as 20 years.
Based on these considerations, we "took a step back" from certain molecular changes reported in previous studies (2) (3) (4) 9, 14, 15) and tried to obtain a broader perspective on the molecular heterogeneity in SLE by immunophenotyping. The heterogeneity of SLE raises 3 clinical questions: 1) What are the differences in immunophenotype between lupus patients and healthy individuals? 2) How do the immune cell phenotypes interact? 3) Can patients be divided into subgroups by immunophenotyping? To address these questions, PB mononuclear cells (PBMCs) were obtained from 143 patients with SLE. Circulating B cells, T cells, natural killer (NK) cells, and DCs were defined based on comprehensive flow cytometric analysis for human immunophenotyping, as described by the Human Immunology Project Consortium (17) .
PATIENTS AND METHODS
Patients. Patients who fulfilled the American College of Rheumatology classification criteria for SLE (18) were enrolled in this study between December 2012 and February 2016. Age-and sex-matched healthy individuals were included as controls. The Human Ethics Review Committee of our university reviewed and approved the study, including the collection of PB samples from healthy controls and SLE patients.
Clinical measurements. Disease activity at baseline was assessed using the SLE Disease Activity Index (SLEDAI) (19, 20) and the British Isles Lupus Assessment Group (BILAG) index (21-23) for organ involvement. Laboratory studies included testing for anti-dsDNA, anti-Sm, IgG, CH50, and C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), leukocyte count, and lymphocyte count. We also collected clinical data and samples after 24 weeks of treatment. Patients who required .2 different immunosuppressive therapies in addition to glucocorticoids were considered to have treatment-resistant disease.
Flow cytometric analysis. All patients in this study were enrolled in the FLOW registry, with immunophenotyping analysis performed by multicolor flow cytometry and the results recorded in the registry. PBMCs were isolated from PB samples using lymphocyte separation medium (ICN/ Cappel Study design. Differences in immunophenotype were evaluated in 143 SLE patients and 49 healthy individuals. To elucidate the diversity among patients with active lupus, 80 patients with severe organ involvement ($1 feature from BILAG category A or $2 from BILAG category B) were identified from the overall group of 143 lupus patients, for principal components analysis (PCA) and cluster analysis. These 80 patients were receiving intensive treatment, such as cyclophosphamide plus glucocorticoids, and 55 of them remained in the study for the full 24-week follow-up period. Changes after treatment were analyzed in samples obtained from these 55 patients at 24 weeks. Supplementary Figure 3 PCA of immunophenotyping data. For easy exploration and visualization of immunophenotyping data, which contained many items, and for estimation of the correlation between variables, we used PCA to statistically aggregate items, reducing the number of observed variables into a smaller number of principal components and reducing the dimensionality of immunophenotyping data. We selected 2 eigenvectors with the highest eigenvalues as PC1 (eigenvalue 5.6) and PC2 (eigenvalue 3.7) based on each contribution rate, although all factors aggregated in 12 eigenvectors. The values for PC1 and PC2 were also calculated in individual SLE patients.
Cluster analysis of lupus patients. Cluster analyses were performed by the Ward method (24), using the immunophenotypes of SLE patients. We determined the number of clusters based on a scree plot, which showed the sum of within-cluster dissimilarities (Supplementary Figure 4 , http://onlinelibrary.wiley.com/doi/10. 1002/art.40180/abstract). The ordinate is the distance that was bridged to join the clusters at each step. There was a natural break where the distance jumps up suddenly, and we defined the break as the cut point. Consequently, we judged that the appropriate number of clusters was 3 and created a tree diagram.
Statistical analysis. Continuous data were expressed as the mean 6 SD, and categorical data as the number (%). The significance of differences between groups was assessed by Student's t-test, with chi-square test used for nominal variables. Analysis of variance was performed among 3 groups. Multiple comparisons were performed by Games-Howell test (if the samples were not homoscedastic) or Tukey's test (if the samples were homoscedastic). Pearson's correlation coefficient was used for correlation analysis. Multivariate analyses were conducted using variables that had P values of less than 0.05 in the univariate analysis. Paired t-tests were used to assess differences between baseline data and data measured at week 24 (with missing data). For assessment of statistical significance of the posttreatment data, nonparametric comparisons were used. P values less than 0.05 were considered significant. All analyses were conducted using JMP version 11.0 (SAS Institute) or SPSS version 22.0 (SPSS).
RESULTS
Baseline characteristics of the patients. Baseline characteristics of the study patients are shown in Supplementary Table 2 (http://onlinelibrary.wiley.com/doi/10. 1002/art.40180/abstract). All were of Asian ethnicity. The mean age was 42.7 years, and most patients were women (89.5%). The mean duration of SLE was 9.5 years; mean disease activity scores at baseline were 11.0 (SLEDAI) and 11.7 (BILAG index). The proportion of patients with $1 BILAG category A feature or $2 BILAG category B features was 61.5%, although 71.3% of the patients were receiving concomitant immunosuppressive medications at baseline. Eight of the 88 patients with $1 BILAG category A feature or $2 BILAG category B features had some missing data and were not included in further analyses. Other laboratory findings included mean anti-dsDNA and IgG levels of 71.7 units/ml and 1,696 mg/dl, respectively, and a mean ESR of 49.1 mm/hour.
Peripheral immune cell phenotype in the patients with SLE. The immunophenotypes of PB from patients with SLE are shown in Figure 1 . Higher proportions of effector memory and activated CD41 T cells, and a lower proportion of central memory CD41 T cells, were Figure 1 . Differences in phenotypes of lymphocytes, monocytes, dendritic cells, and natural killer (NK) cells between patients with systemic lupus erythematosus (SLE) and age-and sex-matched healthy control subjects. Values are the mean 6 SD percentage, with levels that were significantly different in the patient group compared with the healthy control group highlighted in color (blue for decreased; red for increased). P values in the univariate analysis were determined by Student's t-test. Multivariate analyses were performed using variables for which the P values in the univariate analysis were less than 0.05. TEMRA 5 terminally differentiated effector memory cells; Tfh 5 follicular helper T cells.
found in SLE patients compared with healthy subjects. Similarly, the proportions of activated CD81 T cells were higher in SLE patients. We next assessed the properties of functional subsets of CD41 T cells, such as Th1, Th17, Treg, and Tfh cells. Among them, proportions of Treg cells, Tfh cells, activated Th1 cells, activated Treg cells, and activated Tfh cells were higher in SLE patients compared with controls, but no differences in proportions of Th1 and Th17 cells were observed between groups.
Assessment of B cell subsets revealed that the proportion of IgM memory B cells was lower, while that of class-switched memory B cells and IgD-CD27-(double-negative) B cells was higher, in SLE patients than in healthy subjects. Of note, the largest difference in all immune cell phenotypes was observed in the proportion of plasmablasts (16.2% in patients and 3.3% in controls) (Figure 1) .
With regard to DCs, the percentage of myeloid DCs was lower among patients compared with controls, while that of plasmacytoid DCs did not differ between the groups. For NK cells, the proportion of CD16-NK cells was higher in SLE patients, whereas the proportions of monocyte subsets did not differ.
We also investigated the correlation between various immune cells and clinical findings. Moreover, we were able to clarify the correlations among immunophenotypes by focusing on the distances between variables (Figure 2 ). Among these correlations, Th17 and Treg cells were statistically close and showed positive correlation (P , 0.001). Furthermore, Tfh and Th1 cells were also statistically close and showed positive correlation (P 5 0.04). The same pattern was also noted for Tfh cells and plasmablasts (P 5 0.02). The results of PCA indicated that the immunophenotype of SLE patients consists of T cell axis and B cell axis abnormalities.
Statistical cluster analysis based on immunophenotype in SLE. Because SLE is molecularly heterogeneous, targeting of 1 molecule is not an appropriate treatment strategy. Therefore, we next attempted to identify subgroups among the 80 SLE patients with severe organ involvement ($1 feature in BILAG category A or $2 features in BILAG category B).
Cluster analysis revealed that the patients with active SLE could be classified into 3 subgroups ( Figure  3A) . The values in PC1, which was associated with T cell phenotype, and PC2, which was associated with B cell phenotype, in individual patients in the 3 groups are plotted in Figure 3B . The PCA score plot confirmed that SLE patients were clearly separated and localized into 3 regions according to these 2 axes. In addition, if we combined SLE patients and healthy controls in one cluster analysis, the immunophenotype of SLE formed a separate cluster from that of healthy subjects (Supplementary Figure 7 , on the Arthritis & Rheumatology web Next, we explored the immunologic features of the 3 subgroups (Figure 4 and Supplementary Table 5 [http://onlinelibrary.wiley.com/doi/10.1002/art.40180/ abstract]). High proportions of plasmablasts were seen in all groups, to varying extents. However, in 1 group, few changes in T cell differentiation and activation were seen. In particular, the increase in Tfh and Treg cells that was seen among the SLE patients overall was not observed in this group (termed the T cell-independent group). The second group, in which the percentage of plasmablasts was the highest, also had high percentages of Tfh and activated Tfh cells; these elevated percentages appeared in this group exclusively (termed the Tfh-dominant group). In addition, the proportion of activated Th1 cells was the highest in this group. Finally, the third group (termed the Treg-dominant group) exhibited the highest proportions of Th17, activated Treg, and memory Treg cells. Additionally, the proportion of plasmablasts was lower in this group than in either of the other SLE groups (though still increased compared with healthy controls).
Clinical features of the SLE patients in each of the subgroups identified are shown in Table 1 and   Supplementary Table 6 (http://onlinelibrary.wiley.com/ doi/10.1002/art.40180/abstract). There were significant differences in IgG levels (mean 1,720.5 mg/dl, 1,888.9 mg/dl, and 1,270.5 mg/dl) and leukocyte counts (mean 4,697.3/ml, 4,172.0/ml, and 7,955.6/ml among the T cell-independent group, the Tfh-dominant group, and the Treg-dominant group, respectively). However, disease activity indices, such as the SLEDAI and the BILAG index, were comparable ( Table 8 [http://onlinelibrary.wiley.com/doi/10.1002/art. 40180/abstract]). Treatment resulted in markedly decreased proportions of plasmablasts and Tfh cells in the Tfh-dominant group, with the levels of these cells becoming comparable with those in the other groups. Other phenotypes showed the same tendency, i.e., became closer to normal after treatment. However, the features of each group were still evident (e.g., high proportion of activated Treg cells in the Treg-dominant group). Furthermore, cluster analysis revealed that the immunophenotypes of SLE patients remained different from those of healthy controls even after treatment of the patients (Supplementary Figure 9 Table 2 shows the clinical changes after treatment, in the patients grouped according to SLE immunophenotype. Treatment resulted in marked improvement in disease activity indices, such as the SLEDAI and the BILAG index, and the extent of the reduction was comparable among the 3 groups. Other clinical improvements, such as changes in anti-dsDNA, IgG, CH50, and CRP levels and ESR, were also comparable. However, the proportion of SLE patients whose disease was resistant to treatment was highest among the Tfh-dominant group (Table 2 ). Results of statistical cluster analysis based on immune cell phenotypes in patients with systemic lupus erythematosus, classified into the 3 subgroups that were identified. Baseline immunophenotypes in each group are shown. Values are the mean 6 SD percentage, with levels that were significantly different in the patient group compared with the healthy control group highlighted in color (blue for decreased; red for increased). P values in the univariate analysis were determined by one-way analysis of variance. Multinomial logistic regression analyses were performed using variables for which the P values in the univariate analysis were less than 0.05. See Figure 1 for definitions.
DISCUSSION
In rheumatoid arthritis, targeted therapy has made it possible to induce remission in many patients, leading to a paradigm shift in treatment of that disease (25) . However, there has been no published evidence of such an effect of targeted therapy in SLE. Due to the molecular heterogeneity among lupus patients, several clinical trials of potential treatments demonstrated no improvement in patients with SLE (26) (27) (28) (29) . To assess the molecular heterogeneity in SLE, we conducted the present study using PBMCs from SLE patients.
Various phenotype differences were observed among patients with SLE. In addition, there were some correlations between clinical parameters and peripheral cell phenotypes. For instance, the proportion of Tfh cells correlated with the titer of IgG, and that of activated Tfh cells correlated with anti-Sm antibody levels. This might indicate an interaction between activated Tfh and long-lived plasma cells, which promote the production of autoantibodies such as anti-Sm. Furthermore, the proportions of plasmablasts correlated with organ involvement. A landmark study investigating the blood transcriptome of 158 SLE patients identified PCA demonstrated interactions among immunophenotypes in SLE. These interactions were also described in previous reports. For example, an earlier study showed a negative correlation between proportions of Th17 and naive Treg cells (11) . Our study also showed that Th17 and naive Treg cells were at opposite sites of the PCA graph (Figure 2) . Meanwhile, the result that Th17 and activated Treg cells were statistically close indicates the plasticity of Th17 and Treg cells (30, 31) . Similar to the results of many in vivo and in vitro studies showing the importance of Tfh cells in B cell differentiation and pathogenesis of autoimmunity (12, 32) , our data confirmed the importance of the Tfh cell-plasmablast axis in SLE.
In this study, SLE patients could be stratified statistically by immunophenotyping, resulting in 3 immunologic subgroups (the T cell-independent group, the Tfh-dominant group, and the Treg-dominant group), although these clusters have not been validated. The finding that plasmablast proportions were elevated in all 3 groups highlights the fundamental role of plasmablasts in SLE. Further analysis of the 3 groups showed that in the first group (T cell-independent group), there were no characteristic features other than increased plasmablast proportions. Therefore, the most important factor in the pathogenesis of SLE in this group is uncertain. It is possible that neutrophils, which are not included in PBMCs and were not investigated in this study, could play a role in this group. A high percentage of Tfh cells was especially noted in the second group (Tfh-dominant group). The proportion of plasmablasts in this group was also particularly high, and almost all T cells were activated. Moreover, among patients in this group, SLE was resistant to conventional treatment. The third group (Treg-dominant group) had high proportions of activated Treg and memory Treg cells and low proportions of naive Treg cells. Thus, plasticity of Th17 and Treg cells might play an important role in the Treg-dominant group.
Our study has several limitations. First, it was exploratory and was not validated by investigation of other cohorts. Moreover, some of the patients dropped out after treatment and thus could not be included in the follow-up analyses. However, immunophenotypes that had been assessed differently at each institution were standardized through the Human Immunology Project, and this facilitated the comparison of reports from different institutions. Thus, it should be possible to conduct further studies to validate our results. Next, we did not investigate neutrophils. Although abnormality of neutrophil extracellular traps has been reported to play a role in the pathogenesis of SLE (33, 34) , it is difficult to study neutrophils. Finally, we did not investigate secondary lymphoid tissue or actual inflammatory lesions.
Despite these limitations, our results indicate that immunologic abnormalities are not specific in any single SLE patient. However, each abnormality was enhanced by subdividing SLE patients. In other words, the phenotype of lymphocytes was different among the patients, although these patients had similar disease activity. Accumulation of further evidence along these lines will not only contribute to the elucidation of the pathogenesis of SLE, but also help in the development of new treatments.
